HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange’s AIM market (Nasdaq/AIM:HCM; HKEX:13). Receive News & Ratings for ...

HONG KONG and FLORHAM PARK, N.J., April 22, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that it has completed enrollment of ...

HONG KONG - HUTCHMED (China) Limited (Nasdaq/AIM:HCM; HKEX:13) has completed patient enrollment for its Phase II trial of savolitinib, a drug intended for the treatment of gastric cancer with MET ...

Hutchmed (China) is evaluating supply-chain options for a blood-cancer drug recently approved by Beijing to mitigate impact from the ongoing US-China trade war, according to its chief. Last month ...

HONG KONG and FLORHAM PARK, N.J., April 22, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that it has completed enrollment of the ...

Results will be presented at an upcoming scientific conference. HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that new and updated data from ...

Savolitinib is an oral, potent, and highly selective MET tyrosine kinase inhibitor ("TKI") being jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca. MET is a tyrosine ...

HUTCHMED (China) Limited has announced the presentation of new and updated data regarding its compounds savolitinib, fruquintinib, and surufatinib at the upcoming American Association of Cancer ...

HONG KONG - Hutchmed (China) Limited (NASDAQ/AIM:HCM; HKEX:13) has announced that it will present new and updated data from several studies at the American Association for Cancer Research (AACR) ...

HONG KONG - Hutchmed (China) Limited (NASDAQ/AIM:HCM; HKEX:13) has announced that it will present new and updated data from several studies at the American Association for Cancer Research (AACR ...